Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME

Juliano Tiburcio de Freitas,Varsha Thakur,Kathryn M. LaPorte,Vijay S. Thakur,Brian Flores,Valentina Caicedo,Chioma G. E. Ajaegbu,Giuseppe Ingrasci,Zoe M. Lipman,Keman Zhang,Hong Qiu,Thomas R. Malek,Barbara Bedogni
DOI: https://doi.org/10.1186/s13046-024-03214-5
IF: 12.658
2024-11-05
Journal of Experimental & Clinical Cancer Research
Abstract:Immune checkpoint inhibitors (ICI) have dramatically improved the life expectancy of patients with metastatic melanoma. However, about half of the patient population still present resistance to these treatments. We have previously shown Notch1 contributes to a non-inflamed TME in melanoma that reduces the response to ICI. Here, we addressed the therapeutic effects of a novel anti-Notch1 neutralizing antibody we produced, alone and in combination with immune checkpoint inhibition in melanoma models.
oncology
What problem does this paper attempt to address?